INTRODUCTION
============

The relationship between atherosclerosis and inflammation is well established \[[@R1]-[@R3]\]. Inflammation plays a role in plaque formation; even "early atherosclerosis", fatty streaks, consists of macrophage accumulation \[[@R4]\]. Inflammation also has a role in plaque destabilization and rupture \[[@R5],[@R6]\] since macrophages and other inflammatory molecules are increased in symptomatic plaques \[[@R7]\].

Treatment with statins is considered as first line therapy in atherosclerotic disease \[[@R8]-[@R15]\]. Statins also exert anti-inflammatory effects \[[@R9]-[@R17]\].

The aim of this study was to evaluate the inflammatory burden in human carotid artery specimens as well as circulating inflammatory marker levels, in patients on statins and those not receiving these drugs.

PATIENTS AND METHODS
====================

We evaluated patients who underwent carotid endarterectomy for significant (\>70%) carotid bifurcation stenosis. The degree of stenosis was calculated using Digital Subtraction Angiography and the North America Symptomatic Carotid Endarterectomy Collaborators study \[[@R18]\] criteria of evaluation and measurement of carotid artery stenosis. The criteria for patient selection have been described \[[@R19]\].

All patients underwent a computerized tomographic brain study and were examined by the same neurologists. Based on data from history and clinical examination the patients were characterized as symptomatic or asymptomatic. Patients with amaurosis fugax, transient ischemic cerebral symptoms or ipsilateral ischemic stroke were characterized as symptomatic. The remaining patients were characterized as asymptomatic.

Initially, 119 patients scheduled to undergo carotid endarterectomy were evaluated. Five patients that began statin therapy less than 3 months before endarterectomy were excluded from the study. The remaining 114 consecutive patients formed the study population. Fifty three (46%) of them were on statin therapy at least 3 months before endarterectomy. The other 61 (54%) patients had never received statins. The following statins were used: 26 (47%) patients were on atorvastatin (22±11 mg/day), 16 (29%) on simvastatin (27±10 mg/day), 8 (15%) on pravastatin (30±12 mg/day), 2 (4%) on lovastatin (20 mg/day) and 1 (2%) was on fluvastatin (20 mg/day).

The study protocol was approved by the Red Cross Hospital Ethical Committee. Informed consent was obtained from all patients.

LABORATORY ANALYSIS
===================

Blood samples were obtained from all patients the day before endarterectomy, after an overnight fast. The samples were centrifuged for 15 min at approximately 1000 g. Serum was removed, aliquoted immediately and stored at -70° C until tested. Part of the blood sample was used to measure common serum parameters and the lipid profile. Serum interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNFα) concentrations were measured using quantitative sandwich enzyme immunoassay kits (Quantikine HS, R&D Systems, Minneapolis, USA). The lower limit of detection was \<0.1 pg/ml for IL-1β, 0.04 pg/ml for IL-6 and 0.12 pg/ml for TNFα; high sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) were assayed by high sensitivity particle enhanced immunonephelometry (N Latex, Date-Behring Marburg GmbH, Marburg, Germany). The lower limit of detection was 0.18 mg/l for hsCRP and 0.8 mg/l for SAA. Values below the lower detection limit were considered as equal with this limit in the statistical analysis; there were no missing values. The coefficient variations for the assays used were for IL-1β, IL-6, TNFα, hsCRP and SAA 14%, 11%, 22%, 6% and 12%, respectively. Homocysteine levels were determined using an enzymatic assay for the Hitachi 917 analyzer (Roche Diagnostics, Indianapolis, IN 46250, USA), as previously described \[[@R20]\].

CAROTID ENDARTERECTOMY
======================

All carotid endarterectomy procedures were performed by 1 group of vascular surgeons at the Department of Vascular Surgery of the Red Cross Hospital in Athens, from June 2004 to May 2006. Immediately after carotid endarterectomy the specimen was transferred in 0.9% normal saline solution to the laboratory. Transverse sections 4 mm thick were prepared from each atherosclerotic lesion. The section containing the most stenotic part of the bifurcation was labelled 0, while the consecutive parts distally were labelled +1, +2, +3 etc and proximally -1, -2, -3 etc. Each part was embedded in a different paraffin block. Sequential transverse sections 4 μm apart were obtained from each block and stained with haematoxylin and eosin. These sections were used for classification of the atherosclerotic plaque according to the American Heart Association (AHA) criteria \[[@R4]\].

IMMUNOHISTOCHEMISTRY
====================

In order to measure macrophage infiltration of atherosclerotic plaques, we used monoclonal antibodies to a cell marker (CD68, Q-Bend Clone, Dako Corporation, Caprinteria, California, USA). Sequential sections 4 mm apart were evaluated from the atherosclerotic part of each specimen. The number of slides evaluated per patient was 4.1±2.4 (mean±SD). The whole plaque area, excluding parts of the specimen without obvious atherosclerotic lesions, was evaluated at x400 magnification. Evaluation of the images was performed with the Image Tool analysis system (Image Pro Plus, Media Software, Cybernetics, Canada) by 2 independent examiners blinded to the clinical history, and the mean value was recorded. The results were expressed as the proportion of the whole plaque area stained with the monoclonal antibody CD 68.

STATISTICAL ANALYSIS
====================

Continuous parameters are reported as mean ± standard deviation, non parametric variables as median (interquartile interval) and categorical variables as percentages. The t-test or Mann-Whitney test was used for comparing continuous variables between 2 groups, as appropriate. Categorical variables were compared by the chi-square test or Fisher's exact test. The Spearman correlation test was used to assess relationships between variables. A p\<0.05 was considered significant.

RESULTS
=======

Clinical and demographic characteristics of the study population are shown in Table **[1](#T1){ref-type="table"}**. Statin treated patients had lower serum total cholesterol (176±49 vs 202±40 mg/dl, p= 0.011) and low density lipoprotein cholesterol (LDL-C 103±46 vs 127±34 mg/dl, p\<0.001) than patients not receiving these drugs. The 2 groups had no differences in AHA plaque classification and in procedural complications (data not shown).

hsCRP serum levels were significantly lower in patients on statins than in the controls (Table **[2](#T2){ref-type="table"}**). The serum levels of SAA, TNFα, IL-1β and IL-6 did not differ between the 2 study groups (Table **[2](#T2){ref-type="table"}**).

Patients on statin treatment had no differences in the lesion area covered by macrophages compared with patients not receiving these drugs (0.55±0.15% vs 0.49±0.19%, p= 0.21, data not shown). The interobeserver variability was moderate (κ= 0.61±0.09).

DISCUSSION
==========

The main finding of this study is that patients on statins had the same degree of macrophage infiltration of their carotid atherosclerotic plaque with patients not receiving these drugs although serum hsCRP levels were significantly lower.

Several, but not all, studies favour the hypothesis that statins have beneficial effect on macrophage accumulation. Tahara *et al*. \[[@R21]\] using fluorodeoxyglucose positron emission tomography reported that simvastatin reduces the number of inflammation-rich atherosclerotic plaques compared with a placebo group. Crisby *et al*. \[[@R22]\] reported that patients pre-treated with pravastatin had less inflammation in their carotid arteries, compared with patients on placebo. Similar results were reported in monkeys, using simvastatin or pravastatin \[[@R23]\]. On the other hand, Verhoeven *et al*. \[[@R24]\] demonstrated that statin treated patients have increased amount of macrophages in their carotid endarterectomy specimens. However, in patients treated with atorvastatin, the increased amount of CD68 positive cells was not associated with increased protease activity \[[@R24]\]. Our findings are not consistent with either of these hypotheses, since we did not demonstrate any difference in macrophage infiltration between patients receiving statins and those not on these drugs.

hsCRP was lower in patients treated with statins, while the levels of SAA, TNFα, IL-1β and IL-6 were not different between the 2 groups. Statin-induced reduction in hsCRP levels have been demonstrated in many studies in different patient populations \[[@R25]-[@R28]\]. The same is also true for SAA \[[@R29]\] although we did not observe this effect.

Statins are potent anti-inflammatory agents \[[@R2],[@R30]-[@R34]\]. The effect of statins on levels of inflammatory markers was evaluated in a group of hypercholesterolemic patients (n=68) \[[@R35]\]. Compared with diet alone, an 8-week regimen with atorvastatin plus diet recommendation was associated with a significant reduction in plasma levels of TNFα (2.9% vs 21.4%, respectively; p\<0.0001), IL-6 (2.0% vs 22.1%, respectively; p\<0.0001) and IL-1 (2.7% vs 16.4%, respectively; p\<0.0001) \[[@R35]\]. A similar association between statin use and reduction of TNFα and IL-10 plasma levels was recently reported in patients with calcific aortic valve stenosis \[[@R36]\].

STUDY LIMITATIONS
=================

This was a prospective cross sectional study comparing patients receiving statins for more than 3 months with patients who never received these drugs. The different statins, with varying dosage and treatment duration is a limitation. The possible effect of other drugs (like angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers and others) on macrophage accumulation also needs to be considered. The antibody CD68 used to validate macrophages is a non-selective macrophage marker and cannot express the complicated functional status of the macrophages \[[@R24]\]. We also do not know if more aggressive LDL-C lowering would change the results.

CONCLUSIONS
===========

Patients on statins have no differences in macrophage accumulation in carotid atherosclerotic plaques compared with patients who never took these drugs. Inflammatory markers were similar in both groups except for hsCRP which was significantly lower in those individuals taking statins.

###### 

Clinical and Demographic Characteristics of the Statin and Control Groups

                                          Statin Group   Control Group   p
  --------------------------------------- -------------- --------------- ---------
  n                                       53             61              
  Age (years)                             65.7 ± 9.0     67.0 ± 8.3      0.40
  Duration of statin treatment (months)   20 ± 17                        
  **Cardiovascular risk factors**                                        
  Male sex                                42 (79%)       45 (74%)        0.64
  Coronary artery disease                 13 (25%)       6 (10%)         0.07
  Arterial Hypertension                   39 (74%)       49 (80%)        0.53
  Diabetes mellitus                       15 (28%)       14 (23%)        0.66
  Current cigarette smoking               31 (58%)        38 (62%)       0.82
  **Medical treatment**                                                  
  ACE inhibitors                          22 (41%)       22 (36%)        0.69
  ARBs                                    10 (19%)       13 (21%)        0.93
  Beta-blockers                           18 (38%)       14 (23%)        0.27
  Calcium channel blockers                15 (34%)       27 (44%)        0.12
  Diuretics                               10 (19%)       21 (34%)        0.08
  Clopidogrel                             22 (42%)       24 (39%)        0.91
  Aspirin                                 23 (43%)       29 (48%)        0.67
  Diabetes mellitus (oral drugs)          12 (22%)       10 (16%)        0.61
  Diabetes mellitus (insulin)             2 (4%)         3 (5%)          0.91
  **Presence/absence of symptoms**                                       
  Symptomatic                             28 (53%)       31 (51%)        0.86
  Amaurosis Fugax                         1 (2%)         2 (3%)          0.93
  Transient Ischemic Attacks              22 (42%)       23 (38%)        0.95
  Ischemic Stroke                         5 (9%)         6 (10%)         0.86
  Asymptomatic                            25 (47%)       32 (52%)        0.57
  **Serum parameters**                                                   
  Total Cholesterol (mg/dl)               176 ± 49       202 ± 40        0.011
  Low-density lipoprotein (mg/dl)         103 ± 46       127 ± 34        \<0.001
  High-density lipoprotein (mg/dl)        38 ± 6         42 ± 10         0.16
  Triglyceride (mg/dl)                    159 ± 109      154 ± 66        0.86
  Apolipoprotein A (mg/dl)                111 ± 21       118 ± 24        0.23
  Apolipoprotein B (mg/dl)                89 ± 30        96 ± 26         0.11
  Lipoprotein (a) (mg/dl)                 48 ± 52        41 ± 29         0.87
  Homocysteine (µmol/l)                   10.4 ± 3.7     13.0 ± 5.1      0.07
  Creatinine (mg/dl)                      1.00 ± 0.44    1.03 ± 0.47     0.58

ACE, Angiotensin converting enzyme; ARBs, Angiotensin receptor blockers.

###### 

Serum Inflammatory Markers in Statin Treated and Control Patients with Carotid Bifurcation Disease

  Parameter       Statin Treated       Controls             P
  --------------- -------------------- -------------------- ------
  IL-6 (pg/ml)    2.5 \[1.8-4.1\]      2.9 \[1.9-5.2\]      0.24
  TNF-α (pg/ml)   1.3 \[1.0-2.5\]      1.2 \[0.7-2.0\]      0.74
  IL-1b (pg/ml)   0.11 \[0.06-0.41\]   0.12 \[0.06-0.43\]   0.73
  SAA (mg/l)      10.3 \[4.6-22.1\]    11.2 \[3.8-23.6\]    0.48
  hsCRP (mg/l)    1.8 \[1.1-3.4\]      3.4 \[1.3-4.9\]      0.03

IL-6, interleukin 6; TNF-α, tumor necrosis factor-α; IL-1b, interleukin 1b; SAA, serum amyloid A; hsCRP, high sensitivity C-reactive protein.
